Benzinga | Jun 14, 2021 07:17AM EDT

SVB Leerink Maintains Outperform on BeiGene, Raises Price Target to $417

SVB Leerink analyst Andrew Berens maintains BeiGene (NASDAQ:BGNE) with a Outperform and raises the price target from $388 to $417.